HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spero Therapeutics (NASDAQ:SPRO) with a Buy and raises the price target from $5 to $6.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spero Therapeutics (NASDAQ:SPRO) with a Buy and raises the price target from $5 to $6.